Successful desensitization of trimethoprim-sulfamethoxazole in Stenostrophomonas maltophilia osteomyelitis
Allergy, Asthma & Respiratory Disease
; : 218-221, 2014.
Article
in Ko
| WPRIM
| ID: wpr-17991
Responsible library:
WPRO
ABSTRACT
Stenotrophomonas maltophilia is an emerging pathogen associated with morbidity and mortality in hospitalized patients. The treatment of S. maltophilia infection is challenging because clinical isolates are frequently resistant to most antimicrobial agents except trimethoprim-sulfamethoxazole (TMP-SMX). S. maltophilia osteomyelitis is a rare disease and requires a prolonged treatment with TMP-SMX. Here, we report an interesting case of a patient with S. maltophilia osteomyelitis who developed a delayed hypersensitivity reaction during TMP-SMX treatment and successfully treated after desensitization. TMP-SMX desensitization should be considered in patients with hypersensitivity to TMP-SMX, especially when there are no effective alternative drugs in S. maltophilia infection.
Key words
Full text:
1
Database:
WPRIM
Main subject:
Osteomyelitis
/
Trimethoprim, Sulfamethoxazole Drug Combination
/
Mortality
/
Desensitization, Immunologic
/
Stenotrophomonas maltophilia
/
Rare Diseases
/
Hypersensitivity
/
Hypersensitivity, Delayed
/
Anti-Infective Agents
Type of study:
Prognostic_studies
Limits:
Humans
Language:
Ko
Journal:
Allergy, Asthma & Respiratory Disease
Year:
2014
Document type:
Article